What are the opening hours?

Monday 8:30am - 6pm Tuesday 8:30am - 6pm Wednesday 8:30am - 6pm Thursday 8:30am - 6pm Friday 8:30am - 6pm

ivWatch, LLC

Our mission is bold and clear: STOP IV HARM. Continuous monitors exist to keep track of patients’ heart, blood oxygen levels and pulse rates.

ivWatch is redefining IV therapy safety with the only FDA-cleared and CE-marked medical device in the world designed to detect IV infiltrations and extravasations early, before they cause patient harm. ivWatch, LLC is a medical device company focused on improving the safety and effectiveness of intravenous (IV) therapy. IV therapy is a basic yet critical component of care in hospital and outpatient settings, but it has a high failure rate. Until now, no technology has been available to continuously monitor the health of a patient’s IV site, and whether drugs or fluids are being delivered through the vein or leaking into the tissue. The ivWatch Model 400 is a FDA-cleared device to help clinicians monitor the status of a patient’s IV to aid in the early detection of peripheral IV infiltrations and extravasations. Through the use of non-invasive sensor technology, the ivWatch Model 400 can help reduce potentially serious medication dosing errors and associated patient harm from infiltration events. A continuously monitored peripheral IV also offers an alternative to more intrusive vascular access devices when medically indicated. Use of these devices has increased, but can also pose significant risk of harm to patients and greater cost and liability for hospitals. ivWatch has the potential to transform IV therapy by improving patient care and safety, and offering health care providers a much-needed, reliable and cost-effective solution for continuously monitoring peripheral IVs.

04/09/2026

You are either reactive or proactive.

With proven early detection technology at your fingertips, take charge of protecting patients from preventable harm in IV therapy.

So, make the choice... Which one are you?

04/08/2026

Most NICU babies receive a peripheral IV within the first hour of life—their tiny, fragile veins are thin, delicate, and vulnerable from the very start.

For neonates, IV therapy is essential for delivering life-sustaining medications, fluids, and nutrition—but it also carries the risk of infiltration, which can happen quickly and often before visible signs appear.

With ivWatch, clinicians can continuously monitor the IV site in real time, detecting subtle changes early and enabling faster intervention when every second matters.

Protect the smallest patients with an added layer of safety.
Learn more about technology: https://www.ivwatch.com/tech-overview/

04/07/2026

Severe IV injuries aren’t just a patient safety issue—they’re a hidden financial risk, costing hospitals millions each year.

Early detection and prevention can reduce expensive follow-up care like surgeries, extended stays, and ICU days—potentially saving $1.6M–$5.6M annually.

With ivWatch, hospitals get smarter monitoring that protects patients and safeguards margins. Good care is also smart business.

Read more: https://www.ivwatch.com/2026/03/09/ivwatch-and-aon-address-costly-and-underreported-patient-harm-epidemic-with-new-return-on-investment-model/

04/01/2026

Hospitals track CLABSIs relentlessly—dashboards, task forces, financial stakes are all back initiatives. But one of the most common causes of preventable harm remains untracked.

Peripheral IV infiltrations and extravasations (PIVIEs) happen every day—but with no national mandates, reporting requirements, or standardized accountability, clinicians and healthcare facilities are left exposed to increased costs, potential complications, and legal risk.

Early detection changes everything. Surveillance technology gives clinicians time—time to intervene, time to prevent harm.

Read the full article on why PIVIEs must be treated like every other serious hospital‑acquired event: https://www.ivwatch.com/2026/02/27/the-riskiest-silent-hac-in-the-hospital/

03/30/2026

At ivWatch, we’ve seen a clear shift in how hospitals approach IV safety.

Historically, conversations about adopting technologies like ours lived almost exclusively with clinicians. Today, they include risk management, finance teams, and executive leadership. The question has changed from “Does this improve care?” to “What is the cost if we don’t?”

And for many health systems, that cost reaches millions.

What began here in Hampton Roads as a hardware solution to a specific clinical challenge has grown into a data‑driven visibility platform that helps hospitals better understand risk, cost, and the true footprint of IV‑related harm.

Improving outcomes is vital. Transforming how organisations think about safety culture is impact at scale.

Read more: https://www.innovate757.org/2026/03/19/the-hidden-cost-hospitals-couldnt-measure-until-now/

03/26/2026

As a former critical care nurse, Mark Fletcher, RN, BSN has seen firsthand how quickly IV complications can escalate — and how lasting the impact can be.
That experience fuels our mission.

At ivWatch, we’re not just building technology. We’re advancing earlier detection, protecting patients, and giving clinicians greater confidence at the bedside.

Because preventable injuries shouldn’t be part of the outcome.

03/25/2026

ivWatch and Aon have joined forces to reveal the true cost of severe IV infiltration and extravasation injuries — one of healthcare’s most costly and underreported risks.

The new Value Estimation White Paper shows:
•A 93% reduction in IV injury severity with continuous monitoring, backed by a British Medical Journal study
•An $8.9M–$13.4M annual margin impact for a 150-bed pediatric hospital
•A $5.1M–$7.9M impact for non-pediatric hospitals
•A 7x–14x return on investment, even using conservative assumptions

Early detection through ivWatch continuous monitoring not only helps improve patient outcomes but delivers powerful financial returns.

Download the full white paper to see how data-driven IV risk management can transform care and margins:https://www.ivwatch.com/wp-content/uploads/2026/02/AON-ivWatch-Whitepaper.pdf

03/24/2026

In this video, Roland Van Rens explains why the standard "Touch. Look. Compare." approach remains a critical foundation of IV assessment.

But he also explores an important question:
•What additional tools are available to help you truly understand your IV extravasation data?
•If you’re only identifying events at the bedside, are you capturing the full picture?
•Do you know how often they occur, how early they’re detected, and how they’re being graded across your facility?

To improve outcomes, you need visibility into the real scope of the problem.
Read our latest blog: https://www.ivwatch.com/2025/08/11/do-you-know-your-data-are-you-grading-your-pivies/

Because you can’t improve what you don’t measure.

03/19/2026

ivWatch is excited to announce our inclusion in the NHS Supply Chain Innovation Products Pathway in the United Kingdom — progressing through review on an accelerated basis to give NHS Trusts faster access to continuous IV monitoring for early detection of IV infiltration and extravasation events.

Peripheral IV therapy is one of the most common procedures across the NHS, yet IV injuries remain far too frequent. With the right technology, that trajectory can change. Severe IV injury harm is preventable — and the NHS is recognizing that safeguarding patients must remain a top priority.

Maya Aquino-Guerrero, Patient Safety Champion at NHS Supply Chain and National IV and Vascular Access Safety Initiative Board Member, shared:
"In my ongoing efforts to elevate patient safety standards across the NHS, I’ve seen firsthand how early detection technologies like ivWatch can transform IV care. Extravasation injuries are not only painful, but often avoidable with timely intervention. ivWatch’s ability to provide continuous, real-time monitoring empowers clinicians to act quickly, preventing harm and reducing costly complications. This technology embodies the kind of innovation we need to protect patients and ensure the best use of NHS resources."

This milestone helps fast-track proven innovation into frontline care — empowering clinicians, protecting patients, and strengthening IV safety across England.

Read more: https://www.ivwatch.com/2026/03/19/ivwatch-innovative-technology-now-available-through-uk-nhs-supply-chain/

03/18/2026

Peripheral IV infiltration and extravasation events (PIVIEs) remain one of the most common complications in patient care, yet they are rarely tracked with consistency. Different units document differently. Severity gets graded inconsistently. Some events aren’t logged until they become severe.
The result? A massive visibility gap.

Hospitals don’t know their true PIVIE rate—and that means preventable harm stays hidden.

Standardizing post‑event reporting is the simplest, most impactful first step. A unified form captures the essentials: site, medication, severity, time to detection, symptoms, treatment, and outcome. When every unit reports the same way, real patterns finally emerge.

Hospitals that start this process uncover the truth quickly—high‑risk meds, vulnerable populations, and units with elevated rates. From there, strong organizations build PIVIE committees, strengthen protocols, and drive meaningful improvement.

Because preventing IV injuries starts with seeing them.

Read the full article: https://www.ivwatch.com/2026/03/17/why-standardizing-post-pivie-reporting-is-the-first-step-to-preventing-iv-injuries/
Download the standardized Post‑PIVIE Reporting Form:https://www.ivwatch.com/wp-content/uploads/2026/03/IV-Infiltration-Extravasation-Report_fillable_ivwatch_digital.pdf

03/17/2026

The future of IV safety. Our miniaturized sensor brings real-time precision and a smarter, safer standard to IV therapy.

Key Benefits:
• Advanced Monitoring: Continuously surveils the IV site to detect extravasations early.
• Real-Time Alerts: Immediately notifies clinical teams, enabling rapid intervention.
• Enhanced Accuracy: Powered by patented algorithms that provide precise, predictive IV insights.
• Cost-Conscious Impact: Helps reduce IV-related complications, lowering costs and potentially shortening length of stay.

Safer IV therapy starts with better visibility.

Learn more about technology: https://www.ivwatch.com/tech-overview/

03/12/2026

From the smallest patients in neonatal and pediatric units to adult and critical care populations, IV safety matters at every stage of life.

Across the country we're partnering with clinicians, nursing leaders, risk teams, and executives who are committed to reducing preventable IV harm.

What we see everywhere is the same:
Dedicated care teams. Complex patient needs. And a shared desire to detect infiltrations and extravasations earlier.

Whether in pediatrics or adult populations, the goal is consistent — protect patients, support clinicians, and strengthen outcomes.

We’re proud to stand alongside healthcare teams who refuse to accept IV complications as “just part of the process.”

Address

700 Tech Center Parkway, Suite 300
Newport News, VA
23606

Opening Hours

Monday	8:30am - 6pm
Tuesday	8:30am - 6pm
Wednesday	8:30am - 6pm
Thursday	8:30am - 6pm
Friday	8:30am - 6pm

Website

http://www.ivWatch.com/

Alerts

Be the first to know and let us send you an email when ivWatch, LLC posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Practice

Send a message to ivWatch, LLC:

Shortcuts

Want your practice to be the top-listed Clinic in Newport News?

Our Story

ivWatch, LLC is a medical device company focused on improving the safety and effectiveness of intravenous (IV) therapy. IV therapy is a basic yet critical component of care in hospital and outpatient settings, but it has a high failure rate. Continuous monitors exist to keep track of patients’ heart, blood oxygen levels and pulse rates. Until now, no technology has been available to continuously monitor the health of a patient’s IV site, and whether drugs or fluids are being delivered through the vein or leaking into the tissue. The ivWatch Model 400 is a FDA-cleared device to help clinicians monitor the status of a patient’s IV to aid in the early detection of peripheral IV infiltrations and extravasations. Through the use of non-invasive sensor technology, the ivWatch Model 400 can help reduce potentially serious medication dosing errors and associated patient harm from infiltration events. A continuously monitored peripheral IV also offers an alternative to more intrusive vascular access devices when medically indicated. Use of these devices has increased, but can also pose significant risk of harm to patients and greater cost and liability for hospitals. ivWatch has the potential to transform IV therapy by improving patient care and safety, and offering health care providers a much-needed, reliable and cost-effective solution for continuously monitoring peripheral IVs.